Your browser doesn't support javascript.
loading
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt, Susannah L; Bailey, Dyane; Zielinski, John; Apte, Ameya; Musenge, Faith; Karp, Russell; Burke, Shannon; Garcon, Fabien; Mishra, Ankita; Gurumurthy, Sushma; Watkins, Amanda; Arnold, Kristen; Moynihan, James; Clancy-Thompson, Eleanor; Mulgrew, Kathy; Adjei, Grace; Deschler, Katharina; Potz, Darren; Moody, Gordon; Leinster, David A; Novick, Steve; Sulikowski, Michal; Bagnall, Chris; Martin, Philip; Lapointe, Jean-Martin; Si, Han; Morehouse, Chris; Sedic, Maja; Wilkinson, Robert W; Herbst, Ronald; Frederick, Joshua P; Luheshi, Nadia.
Afiliación
  • Hewitt SL; Moderna Inc., Cambridge, Massachusetts.
  • Bailey D; Moderna Inc., Cambridge, Massachusetts.
  • Zielinski J; Moderna Inc., Cambridge, Massachusetts.
  • Apte A; Moderna Inc., Cambridge, Massachusetts.
  • Musenge F; Moderna Inc., Cambridge, Massachusetts.
  • Karp R; Moderna Inc., Cambridge, Massachusetts.
  • Burke S; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Garcon F; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Mishra A; Moderna Inc., Cambridge, Massachusetts.
  • Gurumurthy S; Moderna Inc., Cambridge, Massachusetts.
  • Watkins A; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Arnold K; Moderna Inc., Cambridge, Massachusetts.
  • Moynihan J; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Clancy-Thompson E; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Mulgrew K; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Adjei G; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Deschler K; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Potz D; Moderna Inc., Cambridge, Massachusetts.
  • Moody G; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Leinster DA; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Novick S; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Sulikowski M; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Bagnall C; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Martin P; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Lapointe JM; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Si H; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Morehouse C; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Sedic M; Moderna Inc., Cambridge, Massachusetts.
  • Wilkinson RW; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom.
  • Herbst R; AstraZeneca, Oncology R&D Unit, Gaithersburg, Maryland.
  • Frederick JP; Moderna Inc., Cambridge, Massachusetts. nadia.luheshi@astrazeneca.com Joshua.frederick@modernatx.com.
  • Luheshi N; AstraZeneca, Oncology R&D Unit, Granta Park, Cambridge, United Kingdom. nadia.luheshi@astrazeneca.com Joshua.frederick@modernatx.com.
Clin Cancer Res ; 26(23): 6284-6298, 2020 12 01.
Article en En | MEDLINE | ID: mdl-32817076
PURPOSE: While immune checkpoint inhibitors such as anti-PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models; however, systemic recombinant IL12 had significant toxicity and limited efficacy in early clinical trials. EXPERIMENTAL DESIGN: We therefore designed a novel intratumoral IL12 mRNA therapy to promote local IL12 tumor production while mitigating systemic effects. RESULTS: A single intratumoral dose of mouse (m)IL12 mRNA induced IFNγ and CD8+ T-cell-dependent tumor regression in multiple syngeneic mouse models, and animals with a complete response demonstrated immunity to rechallenge. Antitumor activity of mIL12 mRNA did not require NK and NKT cells. mIL12 mRNA antitumor activity correlated with TH1 tumor microenvironment (TME) transformation. In a PD-L1 blockade monotherapy-resistant model, antitumor immunity induced by mIL12 mRNA was enhanced by anti-PD-L1. mIL12 mRNA also drove regression of uninjected distal lesions, and anti-PD-L1 potentiated this response. Importantly, intratumoral delivery of mRNA encoding membrane-tethered mIL12 also drove rejection of uninjected lesions with very limited circulating IL12p70, supporting the hypothesis that local IL12 could induce a systemic antitumor immune response against distal lesions. Furthermore, in ex vivo patient tumor slice cultures, human IL12 mRNA (MEDI1191) induced dose-dependent IL12 production, downstream IFNγ expression and TH1 gene expression. CONCLUSIONS: These data demonstrate the potential for intratumorally delivered IL12 mRNA to promote TH1 TME transformation and robust antitumor immunity.See related commentary by Cirella et al., p. 6080.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Mensajero / Neoplasias Colorrectales / Linfocitos Infiltrantes de Tumor / Células TH1 / Interleucina-12 / Microambiente Tumoral / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Mensajero / Neoplasias Colorrectales / Linfocitos Infiltrantes de Tumor / Células TH1 / Interleucina-12 / Microambiente Tumoral / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos